Will the PCSK9 Inhibitors Be Employers' "Line in the Sand"?

Area of Science:

• Health Economics
• Pharmacoeconomics
• Drug Management

Background:

• The introduction of novel hepatitis C treatments has heightened employer sensitivity to rising healthcare expenditures.
• Recent launches of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors present new cost management challenges for employers.
• Employers are actively seeking information on PCSK9 inhibitors, including their approved indications and potential for off-label use.

Purpose of the Study:

• To inform corporate employers about the potential financial impact of PCSK9 inhibitors.
• To outline the current landscape of PCSK9 inhibitor utilization and associated costs.
• To guide employers in evaluating strategies for managing expenses related to novel drug classes.

Main Methods:

• Analysis of healthcare expenditure reports, specifically concerning PCSK9 inhibitors.
• Estimation of potential costs based on approved indications and projected off-label use.
• Review of employer sensitivity to new drug classes and their financial implications.

Main Results:

• PCSK9 inhibitors represent a significant new cost factor for employers.
• Off-label use of PCSK9 inhibitors could lead to substantial healthcare expenditures, estimated at $23 billion.
• Based on approved indications, 0.4% of commercial members may be eligible for PCSK9 inhibitors, costing $3.29 per member per month.

Conclusions:

• Corporate employers must proactively evaluate and manage the financial implications of PCSK9 inhibitors.
• Understanding both approved and potential off-label use is crucial for cost containment strategies.
• The introduction of PCSK9 inhibitors necessitates a review of employer healthcare benefit and cost management approaches.